Evidence for Cardiorenal Protection with SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Patients with Diabetic Kidney Disease [PDF]
Journal of Personalized Medicine, 2022 Panagiotis Georgianos +2 more
exaly +2 more sources
Changing the diabetes treatment paradigm from glucose control to cardiorenal protection. [PDF]
Indian J Med Res, 2021 Ekanayake P, Mudaliar S.
europepmc +3 more sources
Dual Inhibition of the Renin–Angiotensin–Aldosterone System and Sodium–Glucose Cotransporter-2: Mechanistic and Clinical Evidence for Cardiorenal Protection [PDF]
BiomedicinesPersoulla Nicolaou
exaly +2 more sources
Cardiorenal benefits of finerenone: protecting kidney and heart
Annals of Medicine, 2023 Persons with diabetes and chronic kidney disease (CKD) have a high residual risk of developing cardiovascular (CV) complications despite treatment with renin-angiotensin system blockers and sodium-glucose cotransporter type 2 inhibitors. Overactivation of mineralocorticoid receptors plays a key role in the progression of renal and CV disease, mainly by
José R. González-Juanatey +5 more
openaire +6 more sources
Frontiers in Endocrinology, 2023 Chronic kidney diseases (CKD) and cardiovascular diseases (CVD) are the main complications in type 2 diabetic mellitus (T2DM), increasing the risk of cardiovascular and all-cause mortality. Current therapeutic strategies that delay the progression of CKD
Ruolin Lv +5 more
doaj +1 more source
The protective effect of apelin-13 on cardiorenal toxicity induced by cyclophosphamide [PDF]
Canadian Journal of Physiology and Pharmacology, 2022 Cyclophosphamide is a chemotherapeutic drug that is widely used in the clinic and can cause multi-organ toxicity. Apelin-13 is an endogenous adipocytokine with antioxidant properties. Therefore, this study investigated the possibility of apelin-13 being a potential therapeutic agent on cardiac toxicity and nephrotoxicity caused by cyclophosphamide. In
Kutlay, Özden +2 more
openaire +3 more sources
The residual cardiorenal risk in type 2 diabetes
Cardiovascular Diabetology, 2021 In this commentary, we introduce the concepts of removed and residual risks in conditioning thecardiorenal outlook of patients with type 2 diabetes (T2D).
Dario Giugliano +3 more
doaj +1 more source
Frontiers in Endocrinology, 2023 Cardio-renal-metabolic (CRM) syndrome, which involves type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD), and heart failure (HF), is a serious healthcare issue globally, with high morbidity and mortality.
Hiroki Akiyama +4 more
doaj +1 more source
Dapagliflozin protects the kidney in a non-diabetic model of cardiorenal syndrome
Pharmacological Research, 2023 Cardiorenal syndrome encompasses a spectrum of disorders involving heart and kidney dysfunction, and sharing common risk factors, such as hypertension and diabetes. Clinical studies have shown that patients with and without diabetes may benefit from using sodium-glucose cotransporter 2 inhibitors to reduce the risk of heart failure and ameliorate renal
Konrad Urbanek +20 more
openaire +6 more sources
Dapagliflozin Ameliorates Neural Damage in the Heart and Kidney of Diabetic Mice
Biomedicines, 2023 (1) Background: Measures for the control of diabetes mellitus (DM) and, especially, for the control of its complications represent a main objective of the research carried out on this disease, since both mortality and morbidity relating to DM represent ...
Ionuț Donoiu +7 more
doaj +1 more source